phrykt

Immix Biopharma, Inc. (IMMX): who owns it and who trades it

As of Nov 16, 2026, IMMX insiders reported 2 purchases worth $10K in the last 12 months. The largest buyer was Gabriel S Morris (CFO), with $5.1K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immix Biopharma

From the latest filings

Overall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMMX

109 funds and institutions reported IMMX shares worth $581M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 18.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Jupiter Topco LLC18.5%
Saturn V Capital Management LP8.8%
Eventide Asset Management, LLC7.3%
State Street Corp5.7%
BlackRock, Inc.5.6%
Deep Track Capital, LP5.2%
Vanguard Capital Management LLC4.7%
Opaleye Management Inc.4.4%
Millennium Management LLC3.9%
UBS Group AG3.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC9.78M18.47%$101MNew
Saturn V Capital Management LP4.66M8.80%$48M+26%
Eventide Asset Management, LLC3.89M7.35%$40.1M+53%
State Street Corp3.00M5.66%$30.9M+1462%
BlackRock, Inc.2.99M5.65%$30.8M+538%
Deep Track Capital, LP2.77M5.24%$28.6MNew
Vanguard Capital Management LLC2.51M4.73%$25.8M+40%
Opaleye Management Inc.2.35M4.43%$24.2MNew
Millennium Management LLC2.07M3.90%$21.3M+18%
UBS Group AG1.94M3.67%$20M+2427%
Marshall Wace, LLP1.79M3.39%$18.5M+9%
T. Rowe Price Associates1.74M3.29%$17.9M+319%
Wellington Management Group LLP1.47M2.78%$15.2MNew
Great Point Partners LLC1.28M2.41%$13.2M+265%
Geode Capital Management, LLC1.20M2.27%$12.4M+159%
Velan Capital Investment Management LP1.08M2.05%$11.2M+47%
Logos Global Management LP1.00M1.89%$10.3M-18%
Bleichroeder LP1.00M1.89%$10.3MNo change
Franklin Resources Inc969,1201.83%$10MNo change
Burkehill Global Management, LP544,1181.03%$5.6M+85%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMMX insiders reported $10K of open-market purchases and $0 of sales.

Purchases, 12 months
$10K
2 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Dec 10, 2025
Filed Dec 10, 2025

Purchases and sales by month

$10K$10KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 10, 2025Ilya M RachmanCEOPurchase746$6.67$5KForm 4
Dec 10, 2025Gabriel S MorrisCFOPurchase770$6.58$5.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Gabriel S MorrisCFO, Director$5.1K–Dec 10, 2025
Ilya M RachmanCEO and Chairman, Director$5K–Dec 10, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMMX short interest

High short interest. 13.4% of IMMX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 250%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.25M IMMX shares were sold short, 13.4% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 9.2 trading days (days to cover).

Shares short, % of all shares

13.4%May 15Oct 3019.7%

Days to cover

9.2May 15Oct 3010.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.25M13.43%+5%1.22M9.2
Oct 15, 202610.71M14.97%+3%1.43M7.5
Sep 30, 202610.39M14.52%+8%2.03M5.1
Sep 15, 20269.62M13.45%No change1.24M7.8
Aug 31, 20269.62M13.44%-7%1.64M5.9
Aug 14, 202610.36M14.48%+9%1.49M7.0
Jul 31, 20269.49M17.92%+12%1.82M5.2
Jul 15, 20268.50M16.05%+8%1.84M4.6
Jun 30, 20267.88M14.88%+99%2.93M2.7
Jun 15, 20263.97M7.49%-2%1.15M3.5
May 29, 20264.03M7.62%+25%1.99M2.0
May 15, 20263.22M6.08%+7%769,8524.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immix Biopharma company events

Immix Biopharma filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 30, 2026.

  1. Sep 30, 2026AnnouncementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering, an aggregate of 11,363,637 shares of its common stock, par value $0.0001 per share at a public… Filing
  2. Sep 29, 2026AnnouncementThe Company announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee. Filing
  3. Jul 20, 2026AnnouncementRichard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Filing
  4. May 29, 2026VoteReported shareholder vote results. Filing
  5. May 21, 2026AnnouncementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering, an aggregate of… Filing
  6. May 21, 2026AnnouncementThe Company announced an update from the Phase 2 NEXICART-2 NXC-201 clinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis patients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative patients have… Filing
  7. Mar 30, 2026AnnouncementThe Company issued a press release announcing that the enrollment for its NEXICART-2 clinical trial of NXC-201 is complete, with topline results expected in Q3 2026. Filing
  8. Mar 25, 2026AgreementImmix Biopharma, Inc., a Delaware corporation and Citizens JMP Securities, LLC entered into Amendment No. 1 to that certain At The Market Offering Agreement, dated June 3, 2025, pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock… Filing
  9. Dec 8, 2025AgreementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto, relating to the issuance and sale of 19,117,646 shares of its common stock, par value $0.0001 per share… Filing
  10. Dec 8, 2025AnnouncementThe Company announced positive phase 2 NXC-201 results in an oral presentation at the American Society of Hematology’s ASH 2025 Annual Meeting, presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. Filing
  11. Nov 26, 2025AnnouncementThis Current Report on Form 8-K is being filed solely to file newly dated consents of KMJ Corbin & Company LLP, formerly the independent registered public accounting firm of Immix Biopharma, Inc., and Crowe LLP, currently the independent registered accounting firm of the Company, each dated… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immix Biopharma financials

Famous investors that hold IMMX

2 of the 50 well-known investors we track reported holding IMMX in their latest 13F filing. The largest position is Ken Griffin's, worth $9.7M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026931,361$9.7M0.0%+84%
Israel Englander · Millennium ManagementQ3 2026865,940$9M0.0%-58%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMMX in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G5.5%
Oct 27, 2026BlackRock, Inc.13G5.5%

Questions about Immix Biopharma, Inc. (IMMX) stock

Who owns the most IMMX stock?

The largest reported owner of Immix Biopharma, Inc. (IMMX) is Jupiter Topco LLC, with 18.5% of the company. In total, 109 funds and institutions reported holding IMMX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IMMX insiders buying or selling?

In the last 12 months, IMMX insiders reported 2 open-market purchases worth $10K and no sales. The latest trade was on Dec 10, 2025. See every trade.

What is the short interest in IMMX?

As of Oct 30, 2026, 11.25M IMMX shares were sold short, 13.4% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 9.2 trading days (days to cover). See the history.

Which famous investors hold IMMX?

2 of the 50 well-known investors we track reported IMMX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $9.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.